Abstract
Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P >.05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.
Original language | English |
---|---|
Pages (from-to) | 547-550 |
Number of pages | 4 |
Journal | Clinical Infectious Diseases |
Volume | 52 |
Issue number | 4 |
DOIs | |
Publication status | Published - 15 Feb 2011 |